Vor Biopharma Inc. (NYSE:VOR) Given Average Rating of “Buy” by Analysts

Shares of Vor Biopharma Inc. (NYSE:VOR) have been assigned an average rating of “Buy” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have covered the stock in the last year is $11.36.

A number of brokerages have commented on VOR. JMP Securities reiterated a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a research report on Tuesday, December 10th. HC Wainwright reiterated a “buy” rating and set a $17.50 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Vor Biopharma in a research note on Monday, December 9th. Finally, Robert W. Baird decreased their target price on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th.

Vor Biopharma Stock Performance

Shares of VOR opened at $1.33 on Friday. Vor Biopharma has a 12 month low of $0.63 and a 12 month high of $2.56. The stock has a fifty day moving average price of $1.04 and a 200 day moving average price of $0.92.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.40) earnings per share for the quarter, hitting the consensus estimate of ($0.40). On average, equities analysts forecast that Vor Biopharma will post -1.42 EPS for the current fiscal year.

Institutional Trading of Vor Biopharma

Large investors have recently bought and sold shares of the business. Renaissance Technologies LLC raised its position in Vor Biopharma by 48.0% in the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock valued at $495,000 after buying an additional 160,642 shares during the last quarter. Exchange Traded Concepts LLC lifted its position in shares of Vor Biopharma by 40.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock valued at $116,000 after buying an additional 48,017 shares during the last quarter. Acadian Asset Management LLC boosted its position in Vor Biopharma by 51.4% during the second quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock worth $79,000 after purchasing an additional 27,597 shares during the period. Rosalind Advisors Inc. purchased a new position in Vor Biopharma in the 3rd quarter valued at approximately $54,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Vor Biopharma in the 2nd quarter worth about $63,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.